Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial

Study (n=401) found both semaglutide 2.4 mg and 1.7mg once a week provided superior and clinically meaningful reductions in bodyweight vs placebo (-13.2% and 9.6% vs -2.1%, p<0.0001 for both) and greater reductions in abdominal visceral fat area (40.0% and 22.2% vs 6.9%).